Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1137940

registered interest
date	09/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services and Social Services: Data Protection
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have, if any, to permit anonymised data (1) controlled, or (2) generated, by publicly funded health and care organisations in the UK to be shared for commercial purposes with businesses headquartered in non-EEA countries after Brexit.
tabling member printed	Lord Freyberg
uin	HL17039
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>Access to patient information for commercial purposes is not permitted, unless the patient has given their consent. The Government's principles governing data-sharing agreements entered into by National Health Service organisations, originally published in draft in December 2018 and reaffirmed in the policy framework update document published earlier this month, make clear that NHS data may only be accessed by third parties where there is an explicit aim to improve the health, welfare and/or care of patients in the NHS or the operation of the NHS, and that a fair share of the benefits from any agreements flow back to the NHS. We do not anticipate this will change when the United Kingdom leaves the European Union.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 17/07/2019 14:08:20 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2593 label Biography information for Lord Freyberg

1137951

registered interest
date	09/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Expectancy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of why the UK had one of the largest slowdowns in improvements in life expectancy between 2011 and 2016 out of the 19 countries analysed by the Office for National Statistics in August 2018.
tabling member printed	Lord Mendelsohn
uin	HL17050
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>Life expectancy is as high as it has ever been in this country, but the rate of increase in life expectancy has slowed down in recent years. To better understand the reasons for the slowdown, the Department commissioned Public Health England to publish <em>A review of recent trends in mortality in England</em>, which includes comparison to other parts of the United Kingdom, the European Union and United States of America. A copy of the review is attached.</p><p>The overall slowdown in improvements is due to a range of factors operating simultaneously across a wide range of age groups, places, and causes of death. Issues include:</p><p> </p><p>- the slowdown in improvement in mortality from heart disease and stroke, which are the leading causes of death. This is partly influenced by the increasing prevalence of diabetes, obesity, and low physical activity;</p><p>- the size and frequency of recent winter peaks in mortality, which were influenced by the intensity and dominant type of influenza circulating, flu vaccine uptake and effectiveness, and is sometimes exacerbated by cold weather, especially among the very elderly people living with conditions such as dementia. Housing and fuel poverty are key to cold weather vulnerability;</p><p>- in younger adults, the cause of death that had the biggest impact was accidental poisoning, a large proportion of these deaths are due to drug misuse; and</p><p>- small increases in mortality rates from chronic lower respiratory disease in males and females, and other causes in males (including cirrhosis and other liver diseases).</p><p> </p><p>The Government remains committed to giving people five extra years of healthy, independent life by 2035 and to ensuring that everyone gets the same great healthcare no matter where they live, backed by our Long Term Plan for the National Health Service.</p> answering member printed Baroness Blackwood of North Oxford question first answered 17/07/2019 13:35:13 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Recent_trends_in_mortality_in_England.pdf title A review of recent trends in mortality in England
tabling member	4286 label Biography information for Lord Mendelsohn

1137952

registered interest
date	09/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mortality Rates: Boys
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the finding of the Office for National Statistics in its mid-year population estimates published in June, that there has been a 14 per cent annual increase in the rate of mortality of boys aged five to nine.
tabling member printed	Lord Mendelsohn
uin	HL17051
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Office for National Statistics data shows that for boys aged five to nine there were 137 deaths in England in the period mid-2017 to mid-2018. This is an increase of 19 deaths compared with the period mid-2016 to mid-2017, when there were 118 deaths. As the number of deaths fluctuate between individual years, a longer period must be looked at for evidence of trends. Public Health England’s review of recent trends in mortality in England, showed that there was an improvement in mortality rates for children aged five to nine between 2011 and 2016. There was also an improvement in early periods, 2001 to 2006, and 2006 to 2011.</p><p>Improving child health outcomes is central to the NHS Long Term Plan and for prioritising services for children and young people. It provides a clear focus on improving the health of children and young people across mental health, learning disabilities, cancer and elsewhere.<strong> </strong></p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 17/07/2019 13:33:57 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4286 label Biography information for Lord Mendelsohn

1137956

registered interest
date	09/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Speech and Language Therapy: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the Secretaries of State for Health and Social Care, Education, and Housing, Communities and Local Government have discussed, or plan to discuss the findings of the Children's Commissioner for England's report We need to talk: Access to speech and language therapy, published on 11 June.
tabling member printed	Lord Ramsbotham
uin	HL17055
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>Colleagues across different Departments meet frequently to discuss a range of topics relating to child wellbeing. The Government recognises that speech, language and communication skills are a primary indicator of child wellbeing and will continue to provide strategic leadership across education, health and social care to narrow inequalities.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 17/07/2019 14:09:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3744 label Biography information for Lord Ramsbotham

1137390

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients.
tabling member printed	Baroness Morgan of Huyton
uin	HL16997
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16998 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137391

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties.
tabling member printed	Baroness Morgan of Huyton
uin	HL16998
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137392

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible.
tabling member printed	Baroness Morgan of Huyton
uin	HL16999
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16998 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137071

registered interest
date	04/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Human Embryo Experiments: Regulation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Earl Howe on 9 October 2013 (HL2237), what assessment the Scientific and Clinical Advances Advisory Committee of the Human Fertilisation and Embryology Authority has made of the regulation of embryoid bodies following the publication of research (1) by Lancaster et al. Cerebral organoids model human brain development and microcephaly in 2013, and (2) in the Nature Cell Biology journal A 3D model of a human epiblast reveals BMP4-driven symmetry breaking on 1 July.
tabling member printed	Lord Alton of Liverpool
uin	HL16935
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Scientific and Clinical Advances Advisory Committee of the Human Fertilisation and Embryology Authority has made no formal assessment of the regulation of embryoid bodies following the publication of research by Lancaster et al. <em>Cerebral organoids model human brain development and microcephaly</em> in 2013, and in the Nature Cell Biology journal <em>A 3D model of a human epiblast reveals BMP4-driven symmetry breaking</em> on 1 July. The publications will be brought to the attention of the Committee.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 17/07/2019 14:17:06 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	738 label Biography information for Lord Alton of Liverpool

1137079

registered interest
date	04/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Dental Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the report by the Care Quality Commission Smiling matters: oral health care in care homes, published on 24 June; and how they intend to respond.
tabling member printed	Lord Hunt of Kings Heath
uin	HL16943
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Government welcomes the report by the Care Quality Commission <em>Smiling matters: oral health care in care homes</em>. The Department together with Public Health England, NHS England and Health Education England is carefully considering the recommendations made in the report and will respond in due course.</p><p>This consideration includes the recommendations that NHS England work with partners in the health and care system to improve access both to high street and, where required domiciliary care for residents of care homes. As well as the recommendation that both local and national monitoring frameworks should include awareness and assessment of oral health including the National Institute of Health and Care Excellence guideline NG48.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned by NHS England locally as an additional service. Where such services have been specifically commissioned any concerns about delivery should be raised with NHS England. NHS England has a duty to provide services to meet local need, including domiciliary services.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16944 HL16945 HL16946 question first answered 17/07/2019 14:11:41 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1137080

registered interest
date	04/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Dental Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to ensure that access to dental provision in care homes is improved.
tabling member printed	Lord Hunt of Kings Heath
uin	HL16944
answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Government welcomes the report by the Care Quality Commission <em>Smiling matters: oral health care in care homes</em>. The Department together with Public Health England, NHS England and Health Education England is carefully considering the recommendations made in the report and will respond in due course.</p><p>This consideration includes the recommendations that NHS England work with partners in the health and care system to improve access both to high street and, where required domiciliary care for residents of care homes. As well as the recommendation that both local and national monitoring frameworks should include awareness and assessment of oral health including the National Institute of Health and Care Excellence guideline NG48.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned by NHS England locally as an additional service. Where such services have been specifically commissioned any concerns about delivery should be raised with NHS England. NHS England has a duty to provide services to meet local need, including domiciliary services.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16943 HL16945 HL16946 question first answered 17/07/2019 14:11:41 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2024 label Biography information for Lord Hunt of Kings Heath